Skip to main content
OpenTrials
Completed

NCT Number: NCT00757029

Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Attention Deficit Disorder With Hyperactivity Attention Deficit and Disruptive Behavior Disorders Mental Disorders Methylphenidate Neurodevelopmental Disorders Pharmacogenetics

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ADHD
  • Physically healthy

Exclusion criteria

  • Neurological illness
  • Concurrent additional psychiatric treatment
  • < IQ 70
  • Psychotic disorder
  • Major mood disorder needed other psychiatric medication
  • Significant suicidal ideation
  • Pervasive developmental disorder

Treatment and study plan

norepinephrine transporter polymorphism,

Genetic

OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism

Other names: OROS methylphenidate (Concerta) monopharmacotherapy, dose : 18-54mg, duration : 8 weeks, genotyping : norepinephrine transporter (SLC6A2) polymorphism

Primary outcomes

  1. Korean ADHD Rating scale-parent version (KARS)

    Time frame: baseline,1,2,4,8 weeks

Secondary outcomes

  1. Barkely side effect rating scale

    Time frame: 1,2,4,8weeks

Sponsors and collaborators

Lead sponsor

Hallym University Medical Center

Other

Registry information

Official study title

Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate

Acronym: NETADHD

Important dates

Study start
2005
Primary completion
2008
Study completion
2010
First posted
Sep 22, 2008
Registry last updated
Oct 5, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.